ClinicalTrials.gg
CompletedNCT01919398Updated Sep 11, 2019Results posted

A Study of LY2940680 in Japanese Participants With Advanced Cancers

A Phase 1 interventional study of LY2940680 in Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Neoplasm Metastasis by Eli Lilly and Company — 7 open to participants now, 16 under way, 7 of them phase 3. Neoplasm Metastasis · Eli Lilly and Company.

Enrollment
56th of 66
19 · median 77
Started
2013
with 2 others
Phase 1
43 of 72
3 open now
Registered
36th of 72
by date

Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2013, is one of 43 in phase 1, and was the 36th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

7 of the 72 studies in Neoplasm Metastasis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neoplasm Metastasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.

03

Conditions studied

  • Neoplasm Metastasis

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or . The participant must be, in the judgment of the investigator, an appropriate candidate for the experimental therapy after available standard therapies have failed to provide clinical benefit for their disease
  • Have the presence of measurable or nonmeasurable disease as defined by the Guideline Version 1.1
  • Have adequate organ function
  • Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy for at least 3 weeks (6 weeks for mitomycin-C or nitrosoureas, 2 weeks for palliative radiation therapy for bone metastasis) prior to study enrollment, and have recovered from the acute effects of any such therapy
  • Males must agree to use medically approved barrier precautions during the study and for 6 months following the last dose of study drug
  • Females with child bearing potential must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of study drug; have had a negative serum pregnancy test ≤7 days before the first dose of study drug
  • A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, the female must stop breastfeeding from the day of the first study drug administration until at least 6 months after the last administration
  • Have an estimated , in the judgment of the investigator, which will permit the participant to complete 2 cycles of treatment
  • Are able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within 21 days of the study enrollment with any agent that has not received regulatory approval for any indication
  • Have symptomatic central nervous system (CNS) or . Participants with treated are eligible if they are clinically stable with regard to neurologic function and off after cranial irradiation ending at least 14 days prior to enrollment, or after surgical resection performed at least 28 days prior to enrollment
  • Have known current hematologic malignancies or acute or chronic leukemia
  • Have a known active fungal, bacterial, and/or known viral infection including human immunodeficiency () or viral (A, B, or C) hepatitis, potentially affecting the conduct of this study
  • Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
  • Have of >470 milliseconds (msec) on screening (ECG)
  • Have serious preexisting medical conditions or serious concomitant systemic disorders that, in the opinion of the investigator, would preclude participation in this study
  • Have received any medication that is a strong inhibitor of cytochrome P4503A4 () within 7 days prior to receiving study drug
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    LY2940680

    Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles. Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

    Drug: LY2940680

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT)

    DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and meets any one of the following criteria based on NCI CTCAE,version 4.0): Grade(Gr) 3 nonhematological toxicity(tox) with exceptions for made for nausea(ns),vomiting(vm),constipation(cp),diarrhea(dr),fatigue(ft),anorexia(an),alopecia or electrolyte-abnormality(eab) that is manageable with appropriate care.If \>Gr 3 ns,vm,cp,dr,ft,an,or eab persists for\>2 days with maximal supportive intervention,the event was declared a DLT.Transient(≤5 days) Gr 3 liver enzyme elevations,without evidence of other hepatic injury.Gr 3 thrombocytopenia(throm) requiring platelet transfusion or Gr 4 throm.Gr 4 neutropenia of \>5 days duration.Febrile neutropenia(ANC\<1,000/mm3 with a single temperature(temp) of \>38.3 degrees C or a sustained temp of ≥38 degrees C for more than one hour).Tox requiring dose omissions of \>5 days or significant \& deemed by the primary investigator(PI) \& sponsor(sp) to be dose limiting .

    Time frame: Cycle 1 (28 Days)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556)

    Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556).

    Time frame: Cycle1 Day1: Predose, 0.5,1,2,4, 6, 8, 10-12 hours; Cycle 1 Day15: Predose, 0.5,1,2,4, 6, 8, 10-12 hours

  2. Pharmacokinetics (PK): Area Under the Concentration Time Curve From 0 to 24 Hours (AUC[0-24]) of LY2940680 and a Major Metabolite of LSN3185556

    Pharmacokinetics (PK): Area Under the Concentration time Curve From 0 to 24 Hours (AUC\[0-24\]) of LY2940680 and a Major Metabolite of LSN3185556.

    Time frame: Cycle1 Day1: Predose, 0.5,1,2,4, 6, 8, 10-12 hours; Cycle 1 Day15: Predose, 0.5,1,2,4, 6, 8, 10-12 hours

  3. Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])

    Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size (\<10 millimeter \[mm\] short axis). PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.

    Time frame: Baseline Until Disease Progression or Death Due to Any Cause (Up to 29 Months)

  4. Pharmacodynamic (PD): Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin

    Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin.

    Time frame: Baseline, Cycle 1 Day15

07

Results

Posted Sep 11, 2019

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
Started3313
Received at least one dose of study drug3313
Completed339
Not completed004
Withdrew: Progressive disease004

Outcome measures

PrimaryNumber of Participants With LY2940680 Dose-Limiting Toxicities (DLT)

DLT was defined as an AE during Cycle 1 that is possibly related to the study drug and meets any one of the following criteria based on NCI CTCAE,version 4.0): Grade(Gr) 3 nonhematological toxicity(tox) with exceptions for made for nausea(ns),vomiting(vm),constipation(cp),diarrhea(dr),fatigue(ft),anorexia(an),alopecia or electrolyte-abnormality(eab) that is manageable with appropriate care.If \>Gr 3 ns,vm,cp,dr,ft,an,or eab persists for\>2 days with maximal supportive intervention,the event was declared a DLT.Transient(≤5 days) Gr 3 liver enzyme elevations,without evidence of other hepatic injury.Gr 3 thrombocytopenia(throm) requiring platelet transfusion or Gr 4 throm.Gr 4 neutropenia of \>5 days duration.Febrile neutropenia(ANC\<1,000/mm3 with a single temperature(temp) of \>38.3 degrees C or a sustained temp of ≥38 degrees C for more than one hour).Tox requiring dose omissions of \>5 days or significant \& deemed by the primary investigator(PI) \& sponsor(sp) to be dose limiting .

Time frame:
Cycle 1 (28 Days)
Reported as:
Count of participants · Participants
Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT)
ParticipantsCohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
Number of Participants With LY2940680 Dose-Limiting Toxicities (DLT)003
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556)

Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556).

Time frame:
Cycle1 Day1: Predose, 0.5,1,2,4, 6, 8, 10-12 hours; Cycle 1 Day15: Predose, 0.5,1,2,4, 6, 8, 10-12 hours
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2940680 and a Major Metabolite of LY2940680 (LSN3185556)
microgram per milliliter (µg/mL)Cohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
LY2940680:Cycle 1 Day 10.841 ± 81.81 ± 53.84 ± 29
LY2940680:Cycle 1 Day 151.41 ± 513.10 ± 219.08 ± 40
LSN3185556:Cycle 1 Day 10.925 ± 451.49 ± 83.02 ± 30
LSN3185556:Cycle 1 Day 152.12 ± 844.10 ± 2213.7 ± 50
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve From 0 to 24 Hours (AUC[0-24]) of LY2940680 and a Major Metabolite of LSN3185556

Pharmacokinetics (PK): Area Under the Concentration time Curve From 0 to 24 Hours (AUC\[0-24\]) of LY2940680 and a Major Metabolite of LSN3185556.

Time frame:
Cycle1 Day1: Predose, 0.5,1,2,4, 6, 8, 10-12 hours; Cycle 1 Day15: Predose, 0.5,1,2,4, 6, 8, 10-12 hours
Reported as:
Geometric mean · microgram*hour per milliliter(µg*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From 0 to 24 Hours (AUC[0-24]) of LY2940680 and a Major Metabolite of LSN3185556
microgram*hour per milliliter(µg*h/mL)Cohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
LY2940680:Cycle 1 Day 17.96 ± 3120.3 ± 2243.1 ± 26
LY2940680:Cycle 1 Day 1514.7 ± 7842.9 ± 40142 ± 61
LSN3185556:Cycle 1 Day 113.2 ± 4824.6 ± 550.1 ± 30
LSN3185556:Cycle 1 Day 1531.8 ± 12679.7 ± 15235 ± 48
SecondaryNumber of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size (\<10 millimeter \[mm\] short axis). PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.

Time frame:
Baseline Until Disease Progression or Death Due to Any Cause (Up to 29 Months)
Reported as:
Count of participants · Participants
Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])
ParticipantsCohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])010
SecondaryPharmacodynamic (PD): Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin

Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin.

Time frame:
Baseline, Cycle 1 Day15
Reported as:
Mean · percentage change
Pharmacodynamic (PD): Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin
percentage changeCohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
Pharmacodynamic (PD): Percentage Change From Baseline in Gene Expression Level of Hedgehog (Hh) Regulated Genes (Gli1) in Skin92.73 ± 0.92889.24 ± 2.09692.86 ± 8.053

Adverse events

Collected over Baseline to End of Study (Up To 2.45 Years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 100 mg LY2940680—0/3 (0%)3/3 (100%)
Cohort 2: 200 mg LY2940680—0/3 (0%)3/3 (100%)
Cohort 3: 400 mg LY2940680—4/13 (30.8%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
ThrombocytopeniaBlood and lymphatic system disorders0/30/31/13
Pericardial effusionCardiac disorders0/30/31/13
PyrexiaGeneral disorders0/30/31/13
Decreased appetiteMetabolism and nutrition disorders0/30/31/13
Cerebral infarctionNervous system disorders0/30/31/13
Cerebrovascular accidentNervous system disorders0/30/31/13
Most frequent other events
Showing 10 of 82
Most frequent other events
EventCohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680
DysgeusiaNervous system disorders3/32/38/13
FatigueGeneral disorders1/30/310/13
Decreased appetiteMetabolism and nutrition disorders1/31/310/13
NauseaGastrointestinal disorders1/31/39/13
ConstipationGastrointestinal disorders2/31/32/13
HaematuriaRenal and urinary disorders0/32/30/13
AlopeciaSkin and subcutaneous tissue disorders1/32/31/13
RashSkin and subcutaneous tissue disorders2/30/30/13
VomitingGastrointestinal disorders0/31/37/13
AnaemiaBlood and lymphatic system disorders0/31/35/13

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680Total
Mean63.7 ± 7.0272.0 ± 4.3660.7 ± 11.9362.9 ± 10.95
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680Total
Female2103
Male121316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680Total
American Indian or Alaska Native0000
Asian331319
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: 100 mg LY2940680Cohort 2: 200 mg LY2940680Cohort 3: 400 mg LY2940680Total
Japan331319
08

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-858-255-5959 Mon - Fri from 9 AM to 5 PM Pacific Time (PST), or speak with your personal physician.
    Shizuoka, 411-8777, Japan
  • For additional information regarding investigative sites for this trial, contact 1-858-255-5959 Mon - Fri from 9 AM to 5 PM Pacific Time (PST), or speak with your personal physician.
    Tokyo, 104-0045, Japan
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of May 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2013
First posted
Aug 9, 2013
Start
Aug 2013
Primary completionActual
May 2016
CompletionActual
Jun 28, 2017
Results first posted
Sep 11, 2019
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01919398
Responsible party
Sponsor
First posted
Aug 9, 2013
Start date
Aug 2013
Primary completion
May 2016
Completion
Jun 28, 2017
Results posted
Sep 11, 2019
Last update
Sep 11, 2019

Study contacts

1-858-255-5959 Mon-Fri from 9 AM to 5 PM Pacific Time (PST)
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion